Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE)

NCT00135876 is registered in ClinicalTrials.gov with Ontario Clinical Oncology Group (OCOG) as lead sponsor.

NCT NCT00135876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00135876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE)
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2002
Completion date
November 30, 2006
Enrollment
512
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumors, venous thromboembolism